Corporate Overview
Allergy Therapeutics®. (AT) is a Europe-based specialty pharmaceutical company focused upon the diagnosis and treatment of allergy. AT has an existing sales base of approximately £33.8m/€43m per annum, an MHRA-approved manufacturing capability and an established sales and marketing infrastructure in several major European markets. In addition, the Company has a number of novel compounds which have already undergone initial clinical evaluation and once registered could potentially revolutionise the treatment of allergy.
- An established range of diagnostics and specific immunotherapy vaccines
- Certain exclusive rights to MPL®, a novel immunological adjuvant in the field of allergy, licensed from Corixa Corporation.
- An innovative product development pipeline supported by documented clinical evidence of efficacy and safety.
- Intellectual property rights to five patent families with further rights to the use of MPL® in new formulations. Patent protection for new products extends to the years 2018-20.
- A highly qualified scientific and commercial team with industry experienced management.
- A European sales and marketing team in Germany, Italy, Spain and UK.
- High quality facilities, including cGMP manufacturing, capable of increased production capacity.
